Oncolytics Biotech (ONCY) Common Equity (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Common Equity data on file, last reported at -$3.8 million in Q4 2025.

• On a quarterly basis, Common Equity fell 188.7% year-over-year to -$3.8 million in Q4 2025; TTM through Dec 2025 was -$3.8 million, a 188.7% decrease from a year earlier, with the FY2025 full-year figure at -$3.8 million, down 215.19% from the prior year.
• Common Equity for Q4 2025 stood at -$3.8 million, down from $83563.0 in the prior quarter.
• Over the last five years, Common Equity for ONCY reached as high as $37.8 million in Q2 2021 and fell as low as -$3.8 million in Q4 2025.
• Historically, Common Equity has averaged $17.6 million across 5 years, with a median of $19.3 million in 2022.
• Across the five-year window, Common Equity surged 61.8% in 2021 and sank 188.7% in 2025, its largest moves.
• Year by year, Common Equity stood at $28.6 million in 2021, then sank by 31.83% to $19.5 million in 2022, then grew by 3.7% to $20.2 million in 2023, then slumped by 78.85% to $4.3 million in 2024, then sank by 188.7% to -$3.8 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were -$3.8 million in Q4 2025, $83563.0 in Q3 2025, and $4.4 million in Q2 2025.